Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia

Journal of Infectious Diseases

Volumn 203, Issue 11, 2011, Pages 1602-1612

  Gu, Lili ^a   Li, Ning ^a   Gong, Jianfeng ^a   Li, Qiurong ^a   Zhu, Weiming ^a   Li, Jieshou ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BERBERINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MYOSIN LIGHT CHAIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL ULTRASTRUCTURE; COLON MUCOSA; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENDOTOXEMIA; ENZYME ACTIVATION; ILEUM MUCOSA; IMMUNOFLUORESCENCE; INTESTINE EPITHELIUM; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; TIGHT JUNCTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; BERBERINE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; ENDOTOXEMIA; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTESTINES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MYOSIN-LIGHT-CHAIN KINASE; TIGHT JUNCTIONS; TRANSCRIPTION FACTOR RELA;

EID: 79956223990     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir147     Document Type: Article

References (40)

1. Fink MP. Effect of critical illness on microbial translocation and gastrointestinal mucosa permeability. Semin Respir Infect 1994; 9:256-60.
2. Yu P, Martin CM. Increased gut permeability and bacterial translocation in Pseudomonas pneumonia-induced sepsis. Crit Care Med 2000; 28:2573-7. (Pubitemid 30604472)
3. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock 2001; 15:1-10.
4. Madara JL. Pathobiology of the intestinal epithelial barrier. Am J Pathol 1990; 137:1273-81.
5. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993; 123:1777-88. (Pubitemid 24012933)
6. Stevenson BR, Siliciano JD, Mooseker MS, Goodenough DA. Identification of ZO-1: a high molecular weight polypeptide associated with the tight junction (zonula occludens) in a variety of epithelia. J Cell Biol 1986; 103:755-66. (Pubitemid 17177325)
7. Furuse M, Sasaki H, Tsukita S. Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 1999; 147:891-903.
8. Li Q, Zhang Q, Wang C, Liu X, Li N, Li J. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol 2009; 218:210-21.
9. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006; 169:1901-9. (Pubitemid 351181952)
10. Moriez R, Salvador-Cartier C, Theodorou V, Fioramonti J, Eutamene H, Bueno L. Myosin light chain kinase is involved in lipopolysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol 2005; 167:1071-9. (Pubitemid 41416259)
11. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006; 290:G496-504.
12. Kong DX, Li XJ, Tang GY, Zhang HY. How many traditional Chinese medicine components have been recognized by modern Western medicine? A chemoinformatic analysis and implications for finding multicomponent drugs. ChemMedChem 2008; 3:233-6.
13. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003; 92:173-6.
14. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 2004; 203:127-37.
15. Shirwaikar A, Shirwaikar A, Rajendran K, Punitha IS. In vitro antioxidant studies on the benzyl tetra isoquinoline alkaloid berberine. Biol Pharm Bull 2006; 29:1906-10.
16. Mantena SK, Sharma SD, Katiyar SK. Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis 2006; 27:2018-27. (Pubitemid 44530576)
17. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10:1344-51. (Pubitemid 40022716)
18. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008; 68:5370-9.
19. Zhang HQ, Wang HD, Lu DX, et al. Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice. Shock 2008; 29:617-22.
20. Cui G, Qin X, Zhang Y, Gong Z, Ge B, Zang YQ. Berberine differentially modulates the activities of Erk, p38 MAPK and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J Biol Chem 2009; 284:28420-9.
21. Kadl A, Pontiller J, Exner M, Leitinger N. Single bolus injection of bilirubin improves the clinical outcome in a mouse model of endotoxemia. Shock 2007; 28:582-8. (Pubitemid 350287444)
22. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 1970; 101:478-83.
23. Chen LW, Wang JS, Hwang B, Chen JS, Hsu CM. Reversal of the effect of albumin on gut barrier function in burn by the inhibition of inducible isoform of nitric oxide synthase. Arch Surg 2003; 138:1219-25. (Pubitemid 37392396)
24. Guttman JA, Li Y, Wickham ME, Deng W, Vogl AW, Finlay BB. Attaching and effacing pathogen-induced tight junction disruption in vivo. Cell Microbiol 2006; 8:634-45. (Pubitemid 43372742)
25. Li N, Gu L, Qu L, et al. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci 2010; 40:1-8.
26. De Plaen IG, Tan XD, Chang H, Wang L, Remick DG, Hsueh W. Lipopolysaccharide activates nuclear factor kappaB in rat intestine: role of endogenous platelet-activating factor and tumour necrosis factor. Br J Pharmacol 2000; 129:307-14. (Pubitemid 30072651)
27. Gu L, Li N, Li Q, et al. The effect of berberine in vitro on tight junctions in human Caco-2 intestinal epithelial cells. Fitoterapia 2009; 80:241-8.
28. Ferrier L, Mazelin L, Cenac N, et al. Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology 2003; 125:795-804. (Pubitemid 37070697)
29. Pritts TA, Moon R, Fischer JE, Salzman AL, Hasselgren PO. Nuclear factor-kappaB is activated in intestinal mucosa during endotoxemia. Arch Surg 1998; 133:1311-5. (Pubitemid 29001293)
30. Ma TY, Boivin MA, Ye D, Pedram A, Said HM. Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005; 288:G422-30.
31. Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J Immunol 2008; 180:5653-61.
32. Shen L, Black ED, Witkowski ED, et al. Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 2006; 119:2095-106. (Pubitemid 43904964)
33. Ralay RH, Carusio N, Wangensteen R, et al. Protection against endotoxic shock as a consequence of reduced nitrosative stress in MLCK210-null mice. Am J Pathol 2007; 170:439-46. (Pubitemid 47339381)
34. Watanabe-Fukuda Y, Yamamoto M, Miura N, et al. Orengedokuto and berberine improve indomethacin-induced small intestinal injury via adenosine. J Gastroenterol 2009; 44:380-9.
35. Li GH, Wang DL, Hu YD, et al. Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. Med Oncol 2010; 37:919-25.
36. Nusrat A, Parkos CA, Verkade P, et al. Tight junctions are membrane microdomains. J Cell Sci 2000; 113:1771-81. (Pubitemid 30333126)
37. Zolotarevsky Y, Hecht G, Koutsouris A, et al. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002; 123:163-72. (Pubitemid 34747537)
38. Han X, Fink MP, Yang R, Delude RL. Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock 2004; 21:261-70.
39. Yang R, Miki K, Oksala N, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol 2009; 297:R362-9.
40. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 2006; 34:2064-72. (Pubitemid 44837767)